Completed PHASE2 INTERVENTIONAL 2-arm NCT00107783

Long-Term Study of Nitisinone to Treat Alkaptonuria

Long-Term Clinical Trial of Nitisinone in Alkaptonuria

Sponsor: National Human Genome Research Institute (NHGRI)

Updated 7 times since 2017 Last updated: Aug 3, 2021 Started: Jan 31, 2005 Primary completion: Apr 30, 2009 Completion: Apr 30, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00107783, this PHASE2 trial focuses on Alkaptonuria and remains completed. Sponsored by National Human Genome Research Institute (NHGRI), it has been updated 7 times since 2005, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Dec 2021 — Jul 2024 [monthly]

Completed PHASE2
Sep 2021 — Dec 2021 [monthly]

Completed PHASE2
Jan 2021 — Sep 2021 [monthly]

Completed PHASE2

▶ Show 2 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Jan 2017 — Jun 2018 [monthly]

Completed PHASE2

First recorded

Jan 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Human Genome Research Institute (NHGRI)

Data source: National Institutes of Health Clinical Center (CC)

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Bethesda, United States